 Our study suggests that unfractionated heparin is the preferred anticoagulant for venoraterial ECMO patients with an APTT monitoring target range of 45 to 80 seconds. However, no significant correlation was observed between APTT levels and the occurrence of thrombotic or bleeding events. Furthermore, the overall incidence of thromboembolic events was high, with more than half of patients not surviving to discharge. This article was authored by Sasarajsik, Robert Breikoff, Benedict Tremel, and others.